The tumor was identified to have MYH9 (exon 37)–ROS1 (exon 35) rearrangement with TP53 mutation at the DNA level by DNA-NGS analysis of lymph node biopsy tissue in March 2023. This evidence concerns the gene MYH9 and neoplasm.